Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials.

Stephen D SilbersteinHans-Christoph DienerDavid W DodickKatherine SommerRichard B Lipton

Published in: Headache (2024)

Participants who achieved <15 monthly headache days with onabotulinumtoxinA treatment achieved meaningful benefits in headache-related disability and migraine-specific quality of life compared with those who remained at or above the 15-monthly headache days threshold. Sustained benefits observed over 56 weeks support long-term onabotulinumtoxinA use for the prevention of CM.

Keyphrases

randomized controlled trial
multiple sclerosis
clinical trial
systematic review
bone marrow
replacement therapy
drug induced
phase iii
smoking cessation